All In Biotech

Free tool

FAERS Monitor: Lisraya

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220106 or its brand name (Lisraya, Brepocitinib Tosylate). Reports on generic versions are filed under their own applications.

Reports

8

Serious

6

75% of reports

Hospitalization

4

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • herpes zoster2
  • acute respiratory failure1
  • blood creatine phosphokinase increased1
  • drug ineffective1
  • dyspnoea1
  • hot flush1
  • interstitial lung disease1
  • malaise1
  • maternal exposure during pregnancy1
  • pyrexia1
  • rash1
  • rhinovirus infection1
  • skin bacterial infection1
  • tachycardia1

Reports by year received

View as table
YearReports
20241
20257

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin bacterial infection13277.4523.3817
rhinovirus infection1675.7108.0168
acute respiratory failure1136.721.833
herpes zoster291.527.6100
blood creatine phosphokinase increased191.314.622
interstitial lung disease154.38.713
hot flush134.95.68
tachycardia129.64.76
maternal exposure during pregnancy129.54.76
pyrexia17.61.21
rash16.01.01
malaise16.01.01
dyspnoea14.60.70
drug ineffective12.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.